404 related articles for article (PubMed ID: 26830009)
1. Therapeutic options in recurrent glioblastoma--An update.
Seystahl K; Wick W; Weller M
Crit Rev Oncol Hematol; 2016 Mar; 99():389-408. PubMed ID: 26830009
[TBL] [Abstract][Full Text] [Related]
2. How did lomustine become standard of care in recurrent glioblastoma?
Weller M; Le Rhun E
Cancer Treat Rev; 2020 Jul; 87():102029. PubMed ID: 32408220
[TBL] [Abstract][Full Text] [Related]
3. Current medical treatment of glioblastoma.
Venur VA; Peereboom DM; Ahluwalia MS
Cancer Treat Res; 2015; 163():103-15. PubMed ID: 25468228
[TBL] [Abstract][Full Text] [Related]
4. Prognostic impact of O6-methylguanine-DNA methyltransferase silencing in patients with recurrent glioblastoma multiforme who undergo surgery and carmustine wafer implantation: a prospective patient cohort.
Metellus P; Coulibaly B; Nanni I; Fina F; Eudes N; Giorgi R; Barrie M; Chinot O; Fuentes S; Dufour H; Ouafik L; Figarella-Branger D
Cancer; 2009 Oct; 115(20):4783-94. PubMed ID: 19637364
[TBL] [Abstract][Full Text] [Related]
5. Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O
Cloughesy T; Finocchiaro G; Belda-Iniesta C; Recht L; Brandes AA; Pineda E; Mikkelsen T; Chinot OL; Balana C; Macdonald DR; Westphal M; Hopkins K; Weller M; Bais C; Sandmann T; Bruey JM; Koeppen H; Liu B; Verret W; Phan SC; Shames DS
J Clin Oncol; 2017 Jan; 35(3):343-351. PubMed ID: 27918718
[TBL] [Abstract][Full Text] [Related]
6. MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial.
Weller M; Tabatabai G; Kästner B; Felsberg J; Steinbach JP; Wick A; Schnell O; Hau P; Herrlinger U; Sabel MC; Wirsching HG; Ketter R; Bähr O; Platten M; Tonn JC; Schlegel U; Marosi C; Goldbrunner R; Stupp R; Homicsko K; Pichler J; Nikkhah G; Meixensberger J; Vajkoczy P; Kollias S; Hüsing J; Reifenberger G; Wick W;
Clin Cancer Res; 2015 May; 21(9):2057-64. PubMed ID: 25655102
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value and kinetics of circulating endothelial cells in patients with recurrent glioblastoma randomised to bevacizumab plus lomustine, bevacizumab single agent or lomustine single agent. A report from the Dutch Neuro-Oncology Group BELOB trial.
Beije N; Kraan J; Taal W; van der Holt B; Oosterkamp HM; Walenkamp AM; Beerepoot L; Hanse M; van Linde ME; Otten A; Vernhout RM; de Vos FY; Gratama JW; Sleijfer S; van den Bent MJ
Br J Cancer; 2015 Jul; 113(2):226-31. PubMed ID: 26042933
[TBL] [Abstract][Full Text] [Related]
8. Current therapeutic options for glioblastoma and future perspectives.
Aquilanti E; Wen PY
Expert Opin Pharmacother; 2022 Oct; 23(14):1629-1640. PubMed ID: 36100970
[TBL] [Abstract][Full Text] [Related]
9. [Treatment of recurrent glioblastoma with single-agent bevacizumab].
Sinkó D; Nemeskéri C
Orv Hetil; 2016 Mar; 157(13):500-3. PubMed ID: 26996897
[TBL] [Abstract][Full Text] [Related]
10. MGMT promoter hypermethylation correlates with a survival benefit from temozolomide in patients with recurrent anaplastic astrocytoma but not glioblastoma.
Sadones J; Michotte A; Veld P; Chaskis C; Sciot R; Menten J; Joossens EJ; Strauven T; D'Hondt LA; Sartenaer D; Califice SF; Bierau K; Svensson C; De Grève J; Neyns B
Eur J Cancer; 2009 Jan; 45(1):146-53. PubMed ID: 18945611
[TBL] [Abstract][Full Text] [Related]
11. Fotemustine and recurrent glioblastoma: possible new opportunities for an old drug.
Addeo R; De Santi MS; Del Prete S; Caraglia M
Cancer Chemother Pharmacol; 2009 Oct; 64(5):863-6. PubMed ID: 19639315
[No Abstract] [Full Text] [Related]
12. Targeted therapy with bevacizumab and erlotinib tailored to the molecular profile of patients with recurrent glioblastoma. Preliminary experience.
D'Alessandris QG; Montano N; Cenci T; Martini M; Lauretti L; Bianchi F; Larocca LM; Maira G; Fernandez E; Pallini R
Acta Neurochir (Wien); 2013 Jan; 155(1):33-40. PubMed ID: 23132371
[TBL] [Abstract][Full Text] [Related]
13. Progression-free and overall survival in patients with recurrent Glioblastoma multiforme treated with last-line bevacizumab versus bevacizumab/lomustine.
Heiland DH; Masalha W; Franco P; Machein MR; Weyerbrock A
J Neurooncol; 2016 Feb; 126(3):567-75. PubMed ID: 26614518
[TBL] [Abstract][Full Text] [Related]
14. The earlier the better? Bevacizumab in the treatment of recurrent MGMT-non-methylated glioblastoma.
Schaub C; Schäfer N; Mack F; Stuplich M; Kebir S; Niessen M; Tzaridis T; Banat M; Vatter H; Waha A; Herrlinger U; Glas M
J Cancer Res Clin Oncol; 2016 Aug; 142(8):1825-9. PubMed ID: 27318492
[TBL] [Abstract][Full Text] [Related]
15. New trends in the medical management of glioblastoma multiforme: the role of temozolomide chemotherapy.
Dehdashti AR; Hegi ME; Regli L; Pica A; Stupp R
Neurosurg Focus; 2006 Apr; 20(4):E6. PubMed ID: 16709037
[TBL] [Abstract][Full Text] [Related]
16. Eight-year survival of a recurrent glioblastoma patient treated with molecularly tailored therapy: a case report.
D'Alessandris QG; Montano N; Martini M; Cenci T; Lauretti L; Stumpo V; Pignotti F; Olivi A; Fernandez E; Larocca LM; Pallini R
Acta Neurochir (Wien); 2018 Dec; 160(12):2387-2391. PubMed ID: 30306271
[TBL] [Abstract][Full Text] [Related]
17. Recurrent Glioblastoma: Combination of High Cerebral Blood Flow with MGMT Promoter Methylation Is Associated with Benefit from Low-Dose Temozolomide Rechallenge at First Recurrence.
Kim C; Kim HS; Shim WH; Choi CG; Kim SJ; Kim JH
Radiology; 2017 Jan; 282(1):212-221. PubMed ID: 27428890
[TBL] [Abstract][Full Text] [Related]
18. The MGMT promoter SNP rs16906252 is a risk factor for MGMT methylation in glioblastoma and is predictive of response to temozolomide.
Rapkins RW; Wang F; Nguyen HN; Cloughesy TF; Lai A; Ha W; Nowak AK; Hitchins MP; McDonald KL
Neuro Oncol; 2015 Dec; 17(12):1589-98. PubMed ID: 25910840
[TBL] [Abstract][Full Text] [Related]
19. [Temozolomide in patients with a glioblastoma multiforme: new developments].
Bromberg JE; Postma TJ
Ned Tijdschr Geneeskd; 2005 Jun; 149(25):1376-8. PubMed ID: 15997689
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of O6-methylguanine-DNA methyltransferase protein expression in patients with recurrent glioblastoma treated with temozolomide.
Nagane M; Kobayashi K; Ohnishi A; Shimizu S; Shiokawa Y
Jpn J Clin Oncol; 2007 Dec; 37(12):897-906. PubMed ID: 18156172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
